Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a Healthcare company (Biotechnology) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
Ultragenyx Pharmaceutical Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.70, Ultragenyx Pharmaceutical Inc. trades at 2.3x sales. Over the last twelve months it generated about $734M of revenue and a net loss of $532M. It runs a gross margin of 82.9%, an operating margin of -64.1% and a net margin of -71.8%. It shows return on equity of 213.2%, return on invested capital of -52.7% and a free cash flow yield of -26.0%. On the balance sheet: a debt-to-equity ratio of -3.15 and a current ratio of 1.40. Over the past 52 weeks the share price ranged from $12.73 to $39.89, with a beta of 0.32.
Ultragenyx Pharmaceutical Inc. does not currently pay a dividend.
34 Wall Street analyst ratings cover the stock: 21 Buy, 12 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Ultragenyx Pharmaceutical Inc. (RARE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 66.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 22.6% / 30% · Interest income / Revenue 1.73% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 66.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 15.0% / 33% · Receivables / Mkt Cap (36m) 9.35% / 49% · Interest income / Revenue 1.73% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 66.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 15.0% / 33.33% · Receivables / Mkt Cap (24m) 9.35% / 33.33% · Interest income / Revenue 1.73% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 91.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 31.5% / 33.33% · Receivables / Avg Assets (4Q) 12.2% / 33.33% · Interest income / Revenue 1.73% / 5% | Fail |
| FTSE | Debt / Total Assets 99.9% / 33.33% · (Cash+ST Inv) / Total Assets 22.4% / 33.33% · (Cash+Recv) / Total Assets 36.4% / 33.33% · Interest income / Revenue 1.73% / 5% | Fail |
No. As of September 2026, Ultragenyx Pharmaceutical Inc. (RARE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Ultragenyx Pharmaceutical Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 1.73% of each dividend: Ultragenyx Pharmaceutical Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.